Ongoing Clinical Trials for Large Cell Lung Cancer Stage IV
There are currently 2 ongoing clinical trials investigating new treatments for large cell lung cancer stage IV. These studies are testing combinations of immunotherapy and chemotherapy drugs to improve patient outcomes. Trials are taking place in Germany, France, and Spain.
Clinical trial locations
- France
- Germany
- Spain
Study on Atezolizumab, Carboplatin, and Etoposide for Adults with Advanced Large-Cell Neuroendocrine Lung Cancer
This trial is investigating a treatment combination for large-cell neuroendocrine carcinoma of the lung, a fast-growing type of cancer. The study combines an immunotherapy drug called Atezolizumab with standard chemotherapy drugs Carboplatin (or Cisplatin) and Etoposide. The main goal is to see how well these treatments work together to improve patient survival.
Who can participate:
You may be eligible if you are at least 18 years old and have been diagnosed with locally advanced or metastatic large-cell neuroendocrine carcinoma that cannot be cured with surgery. The cancer should not have been treated with systemic therapy before, although you may qualify if previous curative treatment ended at least 6 months ago and the cancer has returned. You need to have measurable disease and be able to perform most daily activities independently, with a performance status score between 0 and 2. Your liver, kidney, and blood cell function must meet certain standards.
Who cannot participate:
You cannot join if you have received cancer treatment within the last 4 weeks, have severe allergies to the study drugs, have active infections requiring treatment, are pregnant or breastfeeding, or have participated in another clinical trial recently. You are also excluded if you have serious medical conditions that could interfere with the study, a history of another cancer within the last 5 years unless in remission, untreated or unstable brain metastases, certain autoimmune diseases, or a recent history of drug or alcohol abuse.
Investigational drugs:
Atezolizumab is an immunotherapy medication that helps your immune system recognize and attack cancer cells. It works by blocking a protein that helps cancer cells hide from the immune system. Platinum-based drugs (Carboplatin or Cisplatin) are chemotherapy medications containing platinum that damage cancer cell DNA to stop them from growing. Etoposide is a chemotherapy drug that interferes with cancer cell DNA to prevent them from dividing. All medications are given through an intravenous infusion directly into your bloodstream.
Study on the Safety and Effects of ATL001 and Pembrolizumab in Adults with Advanced Non-Small Cell Lung Cancer
This study is exploring a personalized cell therapy called ATL001, which is designed to target specific mutations in cancer cells. Researchers are testing ATL001 both alone and in combination with pembrolizumab, an established cancer treatment. The main focus is to assess the safety and tolerability of ATL001 while monitoring how well it works against advanced non-small cell lung cancer.
Who can participate:
Eligible participants must be between 18 and 75 years old with a life expectancy of at least 6 months. You should have advanced non-small cell lung cancer that cannot be surgically removed or has spread to other parts of the body, and the cancer must have worsened after standard treatments or you cannot tolerate standard treatments. You must have measurable disease and be well enough to receive treatment with a performance status score of 0 or 1. Before receiving ATL001, you must have been treated with a PD-1/PD-L1 inhibitor medication for at least four doses. The disease should be related to smoking, and you must be medically fit to undergo all study procedures including tissue collection. Female patients of childbearing potential must agree to effective birth control methods during treatment and for specific periods afterward.
Who cannot participate:
You cannot join if you have other types of cancer besides non-small cell lung cancer, fall outside the specified age range, are unable to follow study procedures, or have certain medical conditions that might interfere with the study. You are excluded if you are taking medications that could interfere with the study, are pregnant or breastfeeding, have recently participated in another clinical trial, or have a history of allergic reactions to the study drugs.
Investigational drugs:
ATL001 is a personalized therapy using specially designed immune cells called T cells that are created to recognize and attack cancer cells in patients with advanced non-small cell lung cancer. The therapy is administered through infusion and is currently in early-stage research (phase I/IIa trials). Pembrolizumab is an immunotherapy drug that blocks a protein called PD-1, which prevents the immune system from attacking cancer cells. This medication is already approved for various cancers and belongs to a class of drugs known as immune checkpoint inhibitors. In this trial, pembrolizumab is being studied in combination with ATL001 to evaluate whether the two treatments together can improve outcomes.
Summary
Currently, there are two active clinical trials investigating treatments for large cell lung cancer stage IV. These trials are being conducted in three European countries: Germany, France, and Spain. Both studies focus on combining immunotherapy approaches with other treatments to enhance the body’s ability to fight cancer.
The first trial focuses specifically on large-cell neuroendocrine carcinoma and tests a combination of established chemotherapy drugs with the immunotherapy drug Atezolizumab. This study is being conducted in Germany and aims to evaluate whether adding immunotherapy to standard chemotherapy can improve survival outcomes.
The second trial is exploring a more personalized approach using ATL001, a cell therapy that targets specific cancer mutations, along with pembrolizumab. This study is recruiting patients across multiple countries (France, Germany, and Spain) and represents a newer approach to treating advanced lung cancer by harnessing the patient’s own immune cells.
Both trials reflect the current trend in cancer research toward immunotherapy-based treatments that help the immune system better recognize and attack cancer cells. Patients interested in participating should discuss eligibility criteria with their healthcare providers to determine which trial, if any, may be appropriate for their specific situation.
